No immediate trading catalyst. The name change to Lakefront Biotherapeutics and buyback authorization are symbolic; monitor for actual share repurchases or strategic updates under the new identity.
Price Chart
Executive Summary
Galapagos NV held its Annual and Extraordinary Shareholders' Meetings on April 28, 2026, where all board-proposed resolutions were approved, including a company name change to Lakefront Biotherapeutics effective May 8, 2026, authorization for share buybacks up to 10% of outstanding shares, and renewal of authorized capital up to 20% of share capital. The filing is routine governance with no material financial or operational updates.
Key Facts
- All resolutions proposed by the Board of Directors were approved at the Annual and Extraordinary Shareholders' Meetings on April 28, 2026.
- Company name changed to 'Lakefront Biotherapeutics' effective May 8, 2026.
- Share buyback authorization granted for up to 10% of existing shares, valid for five years.
- Authorized capital renewal approved for up to 20% of share capital, valid for five years.
- Appointment of Mr. Henry Gosebruch as Executive Director, and several independent non-executive directors (Dr. Jane Griffiths, Ms. Dawn Svoronos, Dr. Neil Johnston, Dr. Paulo Fontoura, Mr. Gino Santini) and non-executive director Mr. Devang Bhuva.
- Re-appointment of BDO Bedrijfsrevisoren BV as statutory auditor with annual remuneration of EUR 495,000.
- Annual compensation for non-executive directors set: cash EUR 55,000-110,000 plus equity EUR 135,000.
Financial Impact
No material financial impact. Director compensation changes and auditor fees are immaterial relative to company size.
Risk Factors
- Potential dilution if authorized capital is used for equity issuance.
- No fundamental business update; stock may drift on lack of news.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001104659-26-050978 |
| Document: tm2612973d1_ex99-1.htm | 0001104659-26-050978 |
| Document: 0001104659-26-050978-index-headers.html | 0001104659-26-050978 |
| Document: 0001104659-26-050978-index.html | 0001104659-26-050978 |
| Document: 0001104659-26-050978.txt | 0001104659-26-050978 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 9, 2026 20w ago | 6-K | $28.08 $28.08 | · 0.00% | ▼ −3.89% | $31.95 (+13.78%) |
Jun 9, 2026 20w ago | 6-K | $28.08 $28.08 | · 0.00% | ▼ −1.39% | $31.95 (+13.78%) |
Apr 29, 2026 25w ago | 6-K | $28.08 $28.08 | · 0.00% | ▼ −6.05% | $31.95 (+13.78%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers